“Normal” on a lab report is a reference range, not a personal all-clear. It also is not an invitation to self-diagnose from somebody else's “optimal” list online. Context, trend, and a clinician still get a vote.
“Normal” on a standard blood panel doesn't mean healthy. It means you're not far enough from average to trigger a callback. The reference ranges printed on your results were built by measuring a large cross-section of the population, which includes people with pre-diabetes, subclinical inflammation, early-stage cardiovascular disease, and metabolic dysfunction they haven't been diagnosed with yet. You're being compared to them.
Clinical labs define “normal” as the range containing the middle 95% of test results from that reference population. If the population is metabolically unhealthy (and by most measures, the average American is), then “normal” can include a lot of metabolic risk. It is still a reference interval, not a diagnosis and not a certificate of health.
Longevity medicine approaches this differently. Instead of asking “where does most of the population land?” it asks: where do long-lived, metabolically healthy individuals cluster? Those two questions produce very different answers.
The Gap Between Normal and Optimal
The differences are not subtle. Some longevity clinics use tighter discussion ranges than the lab printout. That can be a useful second look. It is not a treatment target I can assign, and chasing the lowest number is not automatically safer.
Here's how the numbers compare across the markers that matter most for healthspan:
| Biomarker | Clinical “Normal” | Ranges some clinics discuss |
|---|---|---|
| HbA1c | <5.7% | Often <5.7%; lower is not a goal |
| Fasting Insulin | <25 µIU/mL | Trend + context; assays vary |
| Fasting Glucose | 70–99 mg/dL | 72–85 mg/dL |
| LDL Cholesterol | <100 mg/dL | <70 mg/dL |
| ApoB | <90 mg/dL | <60 mg/dL |
| Triglycerides | <150 mg/dL | <100 mg/dL |
| hs-CRP | <3.0 mg/L | <1.0 mg/L |
| Homocysteine | <15 µmol/L | 5–8 µmol/L |
| Vitamin D | >30 ng/mL | 40–80 ng/mL |
| eGFR | >90 mL/min | >90 is already typical; do not chase 100 |
| ALT | <40 U/L | 10–25 U/L |
These are discussion ranges, not prescriptions. HbA1c below 5.7% is the usual nondiabetic reference. Values around 4.0% are not a longevity target and can be a problem on glucose-lowering drugs. Fasting insulin assays are not standardized across labs. Vitamin D above the mid-50s to 80 ng/mL is the high end of what some clinics discuss; do not supplement toward 80 without a clinician. ApoB and LDL targets depend on your overall risk.
Look at fasting insulin. Many lab printouts still use a wide upper limit, so a result that never gets a callback can still be worth a conversation. Insulin resistance can develop before fasting glucose looks odd. The test is also assay-dependent. I would not treat 2–5 µIU/mL as a universal target.
Why Fasting Insulin Is the Most Important Test You're Not Getting
HbA1c catches the downstream effect of chronically elevated blood sugar. Fasting insulin catches the problem upstream, often years or even a decade before glucose abnormalities appear. When insulin climbs to compensate for early resistance, glucose may still look ordinary. That is a reason to ask for context, not a diagnosis I can make from a blog.
Some longevity clinics like to see fasting insulin in the low single digits. That is a research-and-clinic preference, not a validated treatment target, and it does not survive a different lab method. A result in the high teens on a wide reference range is a question for the clinician, not a verdict.
Request it specifically. It's rarely included in a standard metabolic panel.
ApoB vs. LDL: The Better Cardiovascular Marker
LDL cholesterol has been the dominant cardiovascular risk marker for decades. It's also an imperfect one. LDL measures the total cholesterol carried in low-density lipoprotein particles but says nothing about how many particles there are. A small number of large, cholesterol-rich particles can produce the same LDL number as a large number of small, dense particles. The small, dense ones are far more likely to cause arterial damage.
ApoB counts the particles directly. Each LDL particle carries exactly one ApoB protein. An elevated ApoB with a normal LDL is a warning sign that standard cholesterol panels miss entirely. Some prevention-minded clinics aim lower than guideline “acceptable” ApoB numbers. Cumulative ApoB exposure is a serious cardiovascular topic. The exact number still belongs to the clinician who knows your risk, not a table on this page.
The Inflammation Markers Most People Ignore
hs-CRP (high-sensitivity C-reactive protein) measures inflammation in your body. The clinical cutoff around 3.0 mg/L is often used for higher cardiovascular risk strata. Values under 1.0 mg/L are commonly discussed as lower risk. One reading cannot name the cause. Illness, training, and body fat all move it.
Homocysteine sits in a similar blind spot. It's an amino acid byproduct linked to cardiovascular disease, cognitive decline, and DNA damage. Clinical labs flag it only above 15 µmol/L. The some clinics discuss 5–8 µmol/L. A result of 12 may never get a callback. That is a reason to ask, not a reason to start a B-vitamin protocol from a blog.
Homocysteine often falls when B6, B12, or folate intake changes. Lowering the number has not consistently proven that you also lowered heart-attack risk. Treat it as a conversation, not a DIY fix.
Vitamin D: The 30 ng/mL Floor Is Not a Target
The clinical sufficiency threshold for Vitamin D is 30 ng/mL. This was set to prevent deficiency diseases like rickets, not to optimize immune function, bone density, cardiovascular health, or the many other processes Vitamin D regulates.
Some clinics discuss 40–80 ng/mL. That is a discussion range, and 80 is the high end. More is not automatically better. Do not supplement toward a number without a clinician, especially if you already take a multi. Someone at 32 ng/mL may be told they are fine. Whether that is enough for you is a clinical call.
How to Actually Interpret Your Results
The most useful way to read your bloodwork isn't binary (normal/abnormal). It's a four-tier system:
- OptimalInside a tighter discussion range. Still not a diagnosis.
- NormalInside the lab reference range. Worth context if a tighter range was the question.
- AttentionOutside the clinical reference range. Take it to the clinician who ordered the test.
- CriticalFar outside the reference range. Contact the ordering clinician. Do not wait on an app.
This distinction matters because most people in the “Normal” zone assume they have nothing to ask about. They're not sick, so they don't act. I care about this zone because trends can move before a billing code exists. I do not care about it as a way to self-diagnose aging.
The Retesting Schedule That Actually Matters
A single snapshot is useful. A trend is what drives decisions. Retest every 3–6 months: frequent enough to detect trajectory, not so frequent that normal biological variation looks like a trend.
With regular retesting, you're not just asking “where am I?” You're asking “which direction am I moving, and how fast?” That second question is measurably more predictive of long-term health outcomes than any single result.
A fasting insulin that drops from 14 to 8 µIU/mL over six months after a dietary change tells you something no single test result can. An HbA1c moving from 5.1% to 5.4% over two years is still in the usual nondiabetic reference range. It is a trend worth mentioning, not a diagnosis and not a reason to start treating yourself.
What to Do With This
Request a full panel the next time you get bloodwork. Specifically ask for fasting insulin and ApoB; they're rarely ordered without a specific request. Ask for hs-CRP and homocysteine if cardiovascular risk is a concern. Get Vitamin D tested twice a year if you live at a northern latitude.
Then read the results with the clinician who can see the rest of you. The printout is a starting point. A tighter discussion range is a second question, not a second doctor.
Mallet can map uploaded markers against both lab reference ranges and tighter discussion ranges, then show the trend. That is context for a visit. It is not a diagnosis, and it does not write a supplement or medication plan. Get early access →
Selected References
- Timbrell NE. The Role and Limitations of the Reference Interval Within Clinical Chemistry and Its Reliability for Disease Detection. British Journal of Biomedical Science. 2024.
- Nathan DM, et al. Translating the A1C assay into estimated average glucose values. Diabetes Care. 2008.
- Weyer C, et al. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. Journal of Clinical Investigation. 1999.
- Sniderman AD, et al. A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk. Circulation: Cardiovascular Quality and Outcomes. 2011.
- Ference BA, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. European Heart Journal. 2017.
- Ridker PM, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein (JUPITER). New England Journal of Medicine. 2008.
- Homocysteine Lowering Trialists' Collaboration. Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomised trials. BMJ. 1998.
- Schöttker B, et al. Serum 25-hydroxyvitamin D levels and overall mortality. A systematic review and meta-analysis of prospective cohort studies. Ageing Research Reviews. 2012.
This article is for education, not medical advice. Discuss changes to testing or treatment with your clinician.